Helicobacter pylori. Helicobacter pylori [H.pylori] as the cause of diseases classified
Conditions
Interventions
Intervention 1: Fifty four patients received quadruple therapy i.e. azithromycine 250 mg, amoxicillin 500 mg, bismuth subcitrate 240 mg and omeprazole 20 mg bid for 1 week (group A). Intervention 2: S
Treatment - Drugs
Fifty four patients received quadruple therapy i.e. azithromycine 250 mg, amoxicillin 500 mg, bismuth subcitrate 240 mg and omeprazole 20 mg bid for 1 week (group A)
Sixty five patients received quadruple therapy i.e. azithromycine 250 mg, amoxicillin 500 mg, bismuth subcitrate 240 mg and omeprazole 20 mg bid plus diclofenac Na tab, 100 mg daily for 1 week (group
Sixty two received quadruple therapy i.e. azithromycine 250 mg, amoxicillin 500 mg, bismuth subcitrate 240 mg and omeprazole 20 mg bid plus diclofenac Na tab, 100 mg daily for 2 weeks (group C)
Sponsors
Isfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criterion: patients with H.pylori infection. Exclusion criteria: previous treatment for H. pylori infection; use of PPI (proton pomp inhibitors) during 2 weeks and/or antibiotics during 4 weeks before the study; having peptic ulcer, GERD, gastrointestinal malignancy, previous gastro-oesophageal surgery; severe concomitant cardiovascular, hypertention, respiratory or endocrine diseases, clinically significant renal or hepatic disease, haematological disorders; any other clinically significant medical conditions that could increase risk; history of allergy to any of the drug used in the study; pregnancy or lactation; alcohol abuse; drug addiction; severe neurological or psychiatric disorders and contraindication of consumption of NSAID and long-term use of corticosteroids or anti-inflammatory drugs
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication. Timepoint: 4-6 weeks after completion of treatment. Method of measurement: stool antigen assay for H. pylori. | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptoms improvement. Timepoint: 8-10 weeks after treatment. Method of measurement: glasgow dyspepsia severity questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAkbar Arjmandpour
Isfahan University of Medical Sciences
Outcome results
None listed